Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05128383
Other study ID # 2021P000648
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 13, 2023
Est. completion date December 2025

Study information

Verified date July 2023
Source Beth Israel Deaconess Medical Center
Contact Hye Jin Chung, MD
Phone 6176675834
Email hchung6@bidmc.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study investigates the efficacy and safety of dupilumab in the treatment of keloids


Description:

Current scar treatments have limited efficacy and are often unsatisfactory although over $20 billion dollars are spent annually on the treatment and management of scars. Keloids, an abnormal proliferation of scar tissue, can be disfiguring, functionally impairing, and have dramatic impacts on quality of life. Treatments of keloids include a variety of modalities (i.e. intralesional steroid injections, silicone gel or sheets, surgery, laser, radiation therapy, cryotherapy, topical imiquimod, and intralesional 5-fluorouracil injections). However, current treatments are limited to primarily localized interventions. The Investigators hypothesize that dupilumab can decrease the size and symptoms of keloids and improve patient's quality of life. An open-label proof of concept study regarding the use of dupilumab in patients with keloids may be the first step in elucidating a novel systematic approach to treatment of keloids.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Men and women between the ages of 18 and 65 at the time of dupilumab initiation. - Subjects must have either one keloid with = 2 cm length-wise or at least two keloids with = 0.4 cm (width) x 0.4 cm (length) - Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Exclusion Criteria: - History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis (Tb) infection as defined by a positive QuantiFERON TB-Gold test at screening. - Known infection with HIV, hepatitis B or hepatitis C at screening. - Are currently pregnant, breastfeeding, or planning to get pregnant during the study. - Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 8 weeks after stopping treatment. Methods of acceptable birth control are listed below under "Women of Childbearing Potential" - Previous hypersensitivity reaction to dupilumab. - Patients with acute asthma, acute bronchospasm or status asthmaticus. - Patients with known helminth infections. - Currently on any other immunosuppressant systemic medication or within 28 days of baseline visit. - Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy. - Are participating in another study using an investigational agent or procedure during participation in this study or within 28 days prior to baseline visit. - Any other treatment for keloids with 28 days prior to baseline visit, including silicone gel/sheets, laser therapy, intralesional steroid or 5-fluorouracil injections, topical steroid, cryotherapy, surgery, or radiation therapy. - Has had a live vaccine

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dupilumab
Dupilumab a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits interleukin (IL)-4 and IL-13 signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center Regeneron Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient and Observer Scar Assessment Scale (POSAS) Average patient scores for Patient and Observer Scar Assessment Scale (POSAS) from baseline and week 24.
The POSAS measures scar quality by evaluating visual (e.g. color), tactile (e.g. pliability) and sensory (e.g. itch) characteristics of the scar from the perspective of the observer (investigator) and patients. POSAS is comprised of two numeric scales: the Patient Scar Assessment Scale (PSAS, patient scale measuring pain, pruritus, color, stiffness, thickness, bumpiness) and the Observer Scar Assessment Scale (OSAS, observer scale measuring vascularity, pigmentation, thickness, relief, pliability, surface area). Both scales contain six items that are scored numerically on a 1-10 scale. A score of "1" being "no, not at all" and a score of "10" being "yes, very much". Together, they make up the total score (range of 12-120) of the PSAS (range of 6-60) and OSAS (range of 6-60).
Baseline and Week 24
Secondary Vancouver Scar Scale (VSS). Average score of patients for Vancouver Scar Scale (VSS) from baseline and week 24.
Score Description:
The VSS measures four parameters of scars: vascularity, pigmentation, pliability, and height. Each parameter contained ranked subscales that may be summed to obtain a total score ranging from 0 (representing normal skin) to 13 (representing worst scar imaginable).
Vascularity: assessed by looking at the scar at resting and by blanching the scar and observing the rate and amount of blood return
Score 0: normal color and capillary refill
Score 1: pink scar with a slight increase in the local blood supply
Score 2: red scar with a significant increase in the local blood supply
Score 3: purple scar with excess local blood supply, scars which are congested and refill slowly or cannot be completely blanched
Pigmentation: The skin will be blanched with a piece of plastic to eliminate the effect of vascularity on skin color and compared with normal skin (Score: 0-3)
Baseline and Week 24
Secondary Dermatology Life Quality Index (DLQI). Average score patient-reported outcomes based on Dermatology Life Quality Index (DLQI).
Score Description:
A Quality of Life Score will be calculated based upon the Dermatology Life Quality Index (DLQI).
The DLQI is a validated general dermatology questionnaire that consists of 10 items that assess subject health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) (Appendix 3)12. It has been extensively used in dermatology clinical trials for atopic dermatitis. The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Baseline and Week 24
Secondary Histology Histology Description:
Percentage Intensity of expression of the markers will be measured by an image analysis program for patients who have data for both baseline and week 24.
Baseline and Week 24
Secondary Number of patients with keloid volume and size improvement keloid volume and size improvement will be assessed based on photographs taken by Canfield camera analysis software for patients who have data for both baseline and week 24. Baseline and Week 24
See also
  Status Clinical Trial Phase
Recruiting NCT02923596 - Retrospective Study of Keloid Disorder N/A
Completed NCT02922972 - Treatment of Keloid Scar by Autologous Platelet Rich Plasma Obtained With RgenKit-BCT N/A
Terminated NCT01478243 - Study of Psycho-Social Impact of Keloid N/A
Recruiting NCT01423383 - Epidemiology Study of Keloid N/A
Completed NCT03228693 - Gene Expression and Biomarker Profiling of Keloid Skin N/A
Not yet recruiting NCT04326959 - Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Phase 1/Phase 2
Recruiting NCT03312166 - Compressive Device to Prevent Keloïd Scars Recurrence [SCARWARS] N/A
Recruiting NCT02823236 - Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars Phase 3
Recruiting NCT04597060 - The Safety and Efficacy of Thermo-mechanical System for Fractional Ablation Associated Triamcinolone Acetonide Drug Delivery for the Treatment of Hypertrophic Scars and Keloids N/A
Completed NCT05939817 - The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial Phase 4
Completed NCT05887804 - Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial Phase 4
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Recruiting NCT01423981 - Web Based Investigation of Natural History of Keloid Disorder, an Online Survey N/A
Completed NCT01446770 - Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Phase 2
Recruiting NCT06138964 - Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars Phase 3
Enrolling by invitation NCT05461157 - Preoperative Silicone Ointment and Wound Healing N/A
Not yet recruiting NCT04593706 - Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) N/A
Active, not recruiting NCT04988022 - Dupilumab in the Treatment of Keloids Phase 4
Withdrawn NCT02546076 - Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars Phase 2